Drug Approval | May 12, 2022
USFDA approves Lilly and Incyte's Olumiant to treat hospitalised patients with Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
The plan is to advance innovative therapies to drug-resistant cancers
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Subscribe To Our Newsletter & Stay Updated
